| Description | The antibody is directed to target CSF1R for modulating macrophage activation. The antibody inhibits the differentiation of CD163-positive M2- type macrophages. It is not cytotoxic to macrophages but polarizes their differentiation towards the M1 type. The antibody is capable of decreasing MMP-9 secretion by differentiating M2 macrophages. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | Inhib |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CSF1R |
| Alternative Name | Colony Stimulating Factor 1 Receptor; McDonough Feline Sarcoma Viral (V-Fms) Oncogene Homolog; Proto-Oncogene C-Fms; CSF-1 Receptor; CD115 Antigen; EC 2.7.10.1; M-CSF-R; CSF-1R; FMS; Macrophage Colony Stimulating Factor I Receptor |
| Gene ID | 1436 |
| UniProt | P07333 |
| Related pathway | GPCR Pathway and ERK Signaling |
| Research Area | Signal Pathway |
| Related Disease | Leukoencephalopathy, Hereditary Diffuse, With Spheroids 1 and Brain Abnormalities, Neurodegeneration, And Dysosteosclerosis |
